Skip to Content

Singulair (montelukast) Disease Interactions

There are 2 disease interactions with Singulair (montelukast):

Moderate

Montelukast (Includes Singulair) ↔ Liver Disorder

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Reports of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with montelukast sodium that had underlying potential for liver disease, such as alcohol use or other forms of hepatitis. Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast. No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. The pharmacokinetics of montelukast sodium in patients with more severe hepatic impairment or with hepatitis have not been evaluated. Use caution when prescribing montelukast to these patients.

Moderate

Montelukast (Includes Singulair) ↔ Pku

Moderate Potential Hazard, Moderate plausibility

Applies to: Phenylketonuria

Singulair (brand of montelukast) chewable tablets contain 0.842 mg of phenylalanine per each 5 mg tablet. The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

References

  1. "Product Information. Singulair (montelukast)." Merck & Co, Inc, West Point, PA.

Singulair (montelukast) drug Interactions

There are 86 drug interactions with Singulair (montelukast)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide